Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Use Of Gross Rx Prices In Negotiation Picks Would Limit Savings, Erode Rebates – Payers

Executive Summary

United Health Group and CVS strongly object to CMS’s proposed approach to selecting Part D drugs for price negotiation. United Health suggests the agency's method of announcing it will use gross, instead of net, costs could constitute a violation of the Administrative Procedure Act.

You may also be interested in...



Senate Finance Committee PBM Reform Results In ‘Decimal Dust’ Of Savings

A focus on transparency, impacts of vertical integration and concerns about increasing government costs shows in the Congressional Budget Office score of the Senate pharmacy benefits manager reform bill.

Medicare Price Negotiation Will Disrupt Rebating In Part D; The Question Is How Much

Congressional Budget Office maps out how current rebating practices may change in Medicare Part D under the drug pricing provisions of the Inflation Reduction Act.

Medicare Will Pick Drugs For Negotiation Based On Gross Sales, Disadvantaging Highly-Rebated Products

But on the bright side, knowing that eligibility will not be based on net sales to Medicare makes it easier to predict which drugs will be selected first.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel